Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase I...

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials
2016-11-01
Successful listing of LIDE Biotech, invested by Sihuan Pharmaceutical in form of equity participation

Successful listing of LIDE Biotech, invested by Sihuan Pharmaceutical in form of equity participation

2016-09-27
Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

2015-12-24
ShandongXuanZhu Entered into Innovative Research Collaboration with Institute of Immunology of Tsinghua University

Recently,Shandong XuanZhu Pharma Co., Ltd. (“XuanZhu”), a wholly-owned subsidiary of the Group, and the ImmunologyInstitute ofTsinghua University, entered into a novel flexiblecollaboration agreemen...

2015-12-23
ShandongXuanZhu Entered into Innovative Research Collaboration with Institute of Immunology of Tsinghua University

Recently,Shandong XuanZhu Pharma Co., Ltd. (“XuanZhu”), a wholly-owned subsidiary of the Group, and the ImmunologyInstitute ofTsinghua University, entered into a novel flexiblecollaboration agreemen...

2015-11-23
Sihuan Pharmaceutical submits the IND Application for Self-Developed Category 1.1 Innovative Patented Drug –Fadanafil

Recently, Shandong Xuanzhu Pharma Co., Ltd.(“Shandong XuanZhu”), the Group’s innovative drug research anddevelopment division submitted an Investigational New Drug (“IND”)filingofFadanafil(“Fada...

Total 11 Pages  First page  Page up  Page down  Last page

Select

  • 2016
  • 2015
  • 2014
  • 2013
  • 2012